Trial Profile

ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hydroxycarbamide (Primary)
Indications Sickle cell anaemia
Focus Adverse reactions
Acronyms ESCORT-HU Extension
Sponsors addmedica; Theravia

Most Recent Events

27 Aug 2024 Status changed from recruiting to active, no longer recruiting.
12 Dec 2023 Results (n=2923) evaluating the incidence of leg ulcers with prolonged HU treatment in ESCORT-HU and ESCORT-HU extension trial, presented at the 65th American Society of Hematology Annual Meeting and Exposition
12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com